{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:18Z","timestamp":1794047418632,"version":"4.8.0"},"reference-count":29,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly for relapsed or refractory AML. Ex vivo drug sensitivity testing may correlate with outcomes, but its prospective predictive value remains unexplored. Here we report the results of the first stage of the prospective phase II VenEx trial evaluating the utility and predictiveness of venetoclax sensitivity testing using different cell culture conditions and cell viability assays in patients receiving venetoclax-azacitidine. Participants with de novo AML ineligible for intensive chemotherapy, relapsed or refractory AML, or secondary AML were included. The primary endpoint was the treatment response in participants showing ex vivo sensitivity and the key secondary endpoints were the correlation of sensitivity with responses and survival. Venetoclax sensitivity testing was successful in 38\/39 participants. Experimental conditions significantly influenced the predictive accuracy. Blast-specific venetoclax sensitivity measured in conditioned medium most accurately correlated with treatment outcomes; 88% of sensitive participants achieved a treatment response. The median survival was significantly longer for participants who were ex vivo-sensitive to venetoclax (14.6 months for venetoclax-sensitive patients vs. 3.5 for venetoclax-insensitive patients, P&lt;0.001). This analysis illustrates the feasibility of integrating drug-response profiling into clinical practice and demonstrates excellent predictivity. This trial is registered with ClinicalTrials.gov identifier: NCT04267081.<\/jats:p>","DOI":"10.3324\/haematol.2022.281692","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T14:16:39Z","timestamp":1671113799000},"page":"1768-1781","source":"Crossref","is-referenced-by-count":58,"title":["&lt;i&gt;Ex vivo&lt;\/i&gt; venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia"],"prefix":"10.3324","volume":"108","author":[{"given":"Heikki","family":"Kuusanm\u00e4ki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Kyt\u00f6l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"V\u00e4nttinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Ruokoranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Huuhtanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Suvela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annasofia","family":"Holopainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Partanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milla E.L.","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"It\u00e4l\u00e4-Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"V\u00e4strik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Dufva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Siitonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Ettala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja","family":"Py\u00f6r\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Rimpil\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Siitonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kontro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"49137","doi-asserted-by":"crossref","unstructured":"Hourigan CS, Karp JE. Personalized therapy for acute myeloid leukemia. Cancer Discov. 2013; 3(12):1336-1338.","DOI":"10.1158\/2159-8290.CD-13-0832"},{"key":"49138","doi-asserted-by":"crossref","unstructured":"Estey E, Levine RL, L\u00f6wenberg B. Current challenges in clinical development of \u201ctargeted therapies\u201d: the case of acute myeloid leukemia. Blood. 2015; 125(16):2461-2466.","DOI":"10.1182\/blood-2015-01-561373"},{"key":"49139","doi-asserted-by":"crossref","unstructured":"Malani D, Kumar A, Br\u00fcck O. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022; 12(2):388-401.","DOI":"10.1158\/2159-8290.CD-21-0410"},{"key":"49140","doi-asserted-by":"crossref","unstructured":"Tyner JW, Tognon CE, Bottomly D. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018; 562(7728):526-531.","DOI":"10.1038\/s41586-018-0623-z"},{"key":"49141","doi-asserted-by":"crossref","unstructured":"Kornauth C, Pemovska T, Vladimer GI. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 2022; 12(2):372-387.","DOI":"10.1158\/2159-8290.CD-21-0538"},{"key":"49142","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Gil C, Serrano J. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leuk Res. 2019; 76:1-10.","DOI":"10.1016\/j.leukres.2018.11.006"},{"key":"49143","doi-asserted-by":"crossref","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022; 40(1):26-35.","DOI":"10.1016\/j.ccell.2021.12.004"},{"key":"49144","doi-asserted-by":"crossref","unstructured":"Bennett TA, Montesinos P, Moscardo F. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014; 14(4):305-318.","DOI":"10.1016\/j.clml.2013.11.006"},{"key":"49145","doi-asserted-by":"crossref","unstructured":"Snijder B, Vladimer GI, Krall N. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 2017; 4(12):e595-e606.","DOI":"10.1016\/S2352-3026(17)30208-9"},{"key":"49146","doi-asserted-by":"crossref","unstructured":"Kuusanm\u00e4ki H, Lepp\u00e4 A-M, P\u00f6l\u00f6nen P. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020; 105(3):708-720.","DOI":"10.3324\/haematol.2018.214882"},{"key":"49147","doi-asserted-by":"crossref","unstructured":"Karjalainen R, Pemovska T, Popa M. JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 2017; 130(6):789-802.","DOI":"10.1182\/blood-2016-02-699363"},{"key":"49148","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"49149","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Maiti A, Rausch CR. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020; 7(10):e724-e736.","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"49150","doi-asserted-by":"crossref","unstructured":"Stahl M, Menghrajani K, Derkach A. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021; 5(5):1552-1564.","DOI":"10.1182\/bloodadvances.2020003734"},{"key":"49151","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Tiong IS, Quaglieri A. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803.","DOI":"10.1182\/blood.2019003988"},{"key":"49152","doi-asserted-by":"crossref","unstructured":"Pei S, Pollyea DA, Gustafson A. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020; 10(4):536-551.","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"49153","doi-asserted-by":"crossref","unstructured":"Cherry EM, Abbott D, Amaya M. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021; 5(24):5565-5573.","DOI":"10.1182\/bloodadvances.2021005538"},{"key":"49154","doi-asserted-by":"crossref","unstructured":"Spinner MA, Aleshin A, Santaguida MT. Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Blood Adv. 2020; 4(12):2768-2778.","DOI":"10.1182\/bloodadvances.2020001934"},{"key":"49155","doi-asserted-by":"crossref","unstructured":"Seyfried F, Demir S, H\u00f6rl RL. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 2019; 10(8):571.","DOI":"10.1038\/s41419-019-1801-0"},{"key":"49156","doi-asserted-by":"crossref","unstructured":"Bhatt S, Pioso MS, Olesinski EA. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell. 2020; 38(6):872-890.","DOI":"10.1016\/j.ccell.2020.10.010"},{"key":"49157","doi-asserted-by":"crossref","unstructured":"Ferrara F, Barosi G, Venditti A. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013; 27(5):997-999.","DOI":"10.1038\/leu.2012.303"},{"key":"49158","doi-asserted-by":"crossref","unstructured":"Yadav B, Pemovska T, Szwajda A. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014; 4:5193.","DOI":"10.1038\/srep05193"},{"key":"49159","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"49160","doi-asserted-by":"crossref","unstructured":"Stahl M, Menghrajani K, Derkach A. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021; 5(5):1552-1564.","DOI":"10.1182\/bloodadvances.2020003734"},{"key":"49161","doi-asserted-by":"crossref","unstructured":"Zhang H, Nakauchi Y, K\u00f6hnke T. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020; 1(8):826-839.","DOI":"10.1038\/s43018-020-0103-x"},{"key":"49162","doi-asserted-by":"crossref","unstructured":"Bisaillon R, Moison C, Thiollier C. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2019; 34(1):63-74.","DOI":"10.1038\/s41375-019-0485-x"},{"key":"49163","doi-asserted-by":"crossref","unstructured":"Karjalainen R, Liu M, Kumar A. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. Leukemia. 2019; 33(10):2548-2553.","DOI":"10.1038\/s41375-019-0504-y"},{"key":"49164","doi-asserted-by":"crossref","unstructured":"Schumich A, Prchal-Murphy M, Maurer-Granofszky M. Phospho-profiling linking biology and clinics in pediatric acute myeloid leukemia. HemaSphere. 2020; 4(1):e312.","DOI":"10.1097\/HS9.0000000000000312"},{"key":"49165","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Pratz KW, Wei AH. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res. 2022; 28(24):5272-5279.","DOI":"10.1158\/1078-0432.CCR-22-1183"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281692\/75116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281692\/75737","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10906\/75116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:59Z","timestamp":1794045779000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281692","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}